Integrated Environmental Technologies 10-Q 12 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	8-May-15
Document And Entity Information [Abstract]
Entity Registrant Name	INTEGRATED ENVIRONMENTAL TECHNOLOGIES, LTD.
Entity Central Index Key	1084031
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		304,164,263
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

Consolidated_Balance_Sheets_Un

Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Current assets:
Cash	$1,629,158	$371,292
Accounts receivable	96,539	37,098
Prepaid expenses	19,747	11,780
Inventory	95,706	117,690
Other receivable		111,200
Total current assets	1,841,150	649,060
Property and equipment, net	276,163	259,468
Total assets	2,117,313	908,528
Current liabilities:
Accounts payable	255,486	154,167
Accrued expenses	303,310	403,520
Customer deposits	2,000	2,000
Convertible debentures	501,125	501,125
Note payable	26,829	46,546
Total current liabilities	1,088,750	1,107,358
Commitments and contingencies
Stockholders' equity (deficiency):
Common stock, $.001 par value; 400,000,000 shares authorized; 303,992,835 and 253,178,774 shares issued and outstanding, respectively	303,993	253,179
Additional paid-in capital	23,501,035	21,262,811
Accumulated deficit	-22,776,465	-21,714,820
Total stockholders' equity (deficiency)	1,028,563	-198,830
Total liabilities and stockholders' equity (deficiency)	$2,117,313	$908,528

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	303,992,835	253,178,774
Common stock, shares outstanding	303,992,835	253,178,774

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenues:
Sales	$144,077	$12,061
Leasing and Licensing Fees	6,000	6,000
Total revenues	150,077	18,061
Cost of sales	56,430	4,245
Gross profit	93,647	13,816
Operating expenses:
General and administrative	587,709	297,477
Sales and marketing	422,682	160,367
Research and development	134,010	60,890
Total operating expenses	1,144,401	518,734
Loss from operations	-1,050,754	-504,918
Other income (expense):
Interest income	120
Interest expense	-11,011	-12,281
Total other income (expense)	-10,891	-12,281
Net loss	($1,061,645)	($517,199)
Net loss per share, basic and diluted	$0	$0
Weighted average shares outstanding, basic and diluted	279,195,053	230,424,912

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net loss	($1,061,645)	($517,199)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	22,608	21,354
Stock-based compensation expense	375,088	30,437
Changes in operating assets and liabilities:
Accounts receivable	-59,441	4,478
Inventory	-2,267	-4,099
Prepaid expenses	-7,967	19,039
Other receivable	111,200
Accounts payable	101,319	72,035
Accrued expenses	-100,210	-9,118
Net cash used in operating activities	-621,315	-383,073
Cash flows from investing activity:
Purchase of equipment	-15,052
Cash flows from financing activities:
Proceeds from sale of common stock, net of offering costs	1,913,950	25,200
Repayment of note payable	-19,717	-18,387
Net cash provided by financing activities	1,894,233	6,813
Increase (decrease) in cash	1,257,866	-376,260
Cash - beginning of period	371,292	1,049,399
Cash - end of period	1,629,158	673,139
Supplemental disclosure of cash flow information:
Cash paid for interest	6,909	2,139
Cash paid for income taxes	900	700
Noncash operating activities:
Issuance of 206,250 shares of common stock, respectively, as payment of director fees		16,500
Noncash financing activities:
Issuance of 1,055,303 shares of common stock as payment of offering costs related to private placements	56,000
Issuance of warrants to purchase 1,450,303 shares of common stock as payment of offering costs related to private placements	$47,100

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Statement of Cash Flows [Abstract]
Common stock issued as payment of director fees		206,250
Common stock issued as payment offering costs related to private placements	1,055,303
Issuance of warrant to purchase of common stock shares as payment of offering costs related to private placements	1,450,303

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	1. Basis of Presentation
	The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred significant recurring operating losses and negative cash flows from operations. The Company had working capital of $752,400 and an accumulated deficit of $22,776,465 as of March 31, 2015. The Company also has no lending relationships with commercial banks and is dependent on the completion of financings involving the private placement of its securities in order to continue operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
	The Company does not anticipate establishing any lending relationships with commercial banks in the foreseeable future due to its limited operations and assets. The Company continues to execute its primary strategy of selling its anolyte disinfecting solution under the Excelyte® brand name to fund its operations and is focused on obtaining additional capital through the private placement of its securities. The Company is pursuing potential equity and/or debt investors and, from time to time, has engaged placement agents to assist it in this initiative. While the Company is pursuing the opportunities and actions described above, there can be no assurance that it will be successful in its efforts. If the Company is unable to secure additional capital, it will explore other strategic alternatives, including, but not limited to, the sale of the Company. Any additional equity financing may result in substantial dilution to the Company’s stockholders.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventory	2. Inventory
	As of March 31, 2015 and December 31, 2014, inventory consisted of parts and materials totaling $95,706 and $117,690, respectively.

Property_and_Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	3. Property and Equipment
	As of March 31, 2015 and December 31, 2014, property and equipment, on a net basis, consisted of the following:
		31-Mar-15			31-Dec-14
	Leasehold improvements	$	328,977		$	328,977
	Equipment		476,807			437,504
			805,784			766,481
	Less: Accumulated depreciation		(529,621	)		(507,013	)
		$	276,163		$	259,468

Accrued_Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Accrued Expenses	4. Accrued Expenses
	As of March 31, 2015 and December 31, 2014, accrued expenses consisted of the following:
		31-Mar-15		31-Dec-14
	Accrued compensation	$	232,979	$	253,305
	Accrued penalty		-		87,344
	Accrued interest (see Note 5)		37,453		27,321
	Accrued professional fees		2,750		22,000
	Accrued consulting fees and other expenses		30,128		13,550
		$	303,310	$	403,520

Convertible_Debentures

Convertible Debentures	3 Months Ended
	Mar. 31, 2015
Convertible Debentures [Abstract]
Convertible Debentures	5. Convertible Debentures
	April 2007 Convertible Debenture
	On April 26, 2007, in a private placement, the Company issued a convertible debenture to an individual accredited investor in the principal amount of $25,000. This convertible debenture matured on January 2, 2009 and remains unpaid. The convertible debenture accrues interest at a rate of 12% per annum and is convertible at any time into shares of the Company’s common stock at the option of the holder at a conversion price of $0.40 per share. An aggregate of 62,500 shares of the Company’s common stock can be issued upon the conversion of the outstanding principal amount due on this convertible debenture at the current conversion price of $0.40 per share.
	During each of the three months ended March 31, 2015 and 2014, the Company recorded a total of $740 of interest expense related to this convertible debenture. As of March 31, 2015 and December 31, 2014, the outstanding principal on this convertible debenture was $25,000, which was included as a component of current convertible debentures, and the accrued and unpaid interest was $14,181 and $13,441, respectively, which was included as a component of accrued expenses (see Note 4).
	Zanett Convertible Debentures
	On August 21, 2012, the Company issued to Zanett Opportunity Fund, Ltd. (“Zanett”) an 8% convertible debenture in the amount of $476,125 (the “Zanett August 2012 Debenture”). In connection with this private placement, the Company refinanced an 8% convertible debenture, in the principal amount of $376,125, issued to Zanett on July 7, 2011 (the “Zanett July 2011 Debenture”) and refinanced an 8% convertible secured promissory note, in the principal amount of $100,000, issued to Zanett on September 23, 2011 (the “Zanett September 2011 Note”). As a result of the issuance of the Zanett August 2012 Debenture, the Zanett July 2011 Debenture and the Zanett September 2011 Note were cancelled.
	The Zanett August 2012 Debenture has a three-year term maturing on August 21, 2015 and bears interest at a rate of 8% per annum. Interest is payable in annual installments in cash or, at the option of the Company, in shares of the Company’s common stock. If the Company elects to pay the interest in shares of its common stock, the number of shares issued as payment will be equal to the quotient of the unpaid interest divided by the market price of the Company’s common stock, as defined in the Zanett August 2012 Debenture.
	The entire principal amount of the Zanett August 2012 Debenture is convertible at any time into shares of the Company’s common stock at the option of the holder at a conversion price of $0.10 per share. In addition, at the option of the Company, the entire principal amount of the Zanett August 2012 Debenture is convertible into shares of the Company’s common stock at $0.10 per share upon the occurrence of the merger or acquisition of the Company or if the average closing price of the Company’s common stock for any period of ten consecutive trading days is greater than or equal to $0.15 per share. The quoted market price of the Company’s common stock on August 21, 2012 was $0.05 per share. An aggregate of 4,761,250 shares of the Company’s common stock can be issued upon the conversion of the outstanding principal amount due on the Zanett August 2012 Debenture at the current conversion price of $0.10 per share.
	During each of the three months ended March 31, 2015 and 2014, the Company recorded $9,392 of interest expense related to the Zanett August 2012 Debenture. As of March 31, 2015 and December 31, 2014, the outstanding principal on the Zanett August 2012 Debenture was $476,125, which was included as a component of current convertible debentures, and the accrued and unpaid interest was $23,272 and $13,880, respectively, which was included as a component of accrued expenses (see Note 4).

Note_Payable

Note Payable	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Note Payable	6. Note Payable
	On June 17, 2013, the Company and Benchmark Performance Group, Inc. (“Benchmark”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”), whereby the Company purchased nineteen EcaFlo™ machines owned by Benchmark as well as the rights to the Excelyte® trademark and certain other intangible assets. The purchase price for the nineteen EcaFlo™ machines, the Excelyte® trademark and other intangible assets was $190,000.
	The Company paid $38,000 in conjunction with the closing of the Asset Purchase Agreement and issued a promissory note with a principal balance of $152,000 (the “Benchmark Note”). The Benchmark Note bears interest at a rate of 7% per annum and requires the Company to make twenty-four monthly payments of $6,805 commencing August 1, 2013. The Benchmark Note is secured by the nineteen EcaFlo™ machines.
	For the three months ended March 31, 2015 and 2014, the Company recorded $6,852 and $2,029, respectively, of interest expense related to the Benchmark Note. As of March 31, 2015 and December 31, 2014, the outstanding principal on the Benchmark Note was $26,829 and $46,546, respectively.

Stockholders_Equity_Deficiency

Stockholders' Equity (Deficiency)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Stockholders' Equity (Deficiency)	7. Stockholders’ Equity (Deficiency)
	Common Stock
	Sale of Common Stock and Common Stock Units
	On February 9, 2015, the Company sold (a) an aggregate of 36,500,000 shares of common stock for an aggregate purchase price of $1,460,000, or $0.04 per share, and (b) common stock units that in aggregate consisted of 7,575,758 shares of common stock and warrants to purchase 3,787,880 shares of common stock for an aggregate purchase price of $500,000, or $0.066 per share.
	The warrants have a three-year term, are exercisable at $0.066 per share and were fully vested at the date of issuance. In addition, the warrants are callable by the Company in the event that the closing price of its common stock for at least fifteen trading days in any consecutive twenty-trading-day period is equal to or greater than $0.132, provided that at least six months have lapsed from the issuance date of the warrants (see Warrants to Purchase Common Stock).
	The Company paid an aggregate of $46,050 of offering costs in cash, issued an aggregate of 1,055,303 shares of common stock as payment of $56,000 of offering costs and issued warrants to purchase an aggregate of 1,450,303 shares of common stock (see Warrants to Purchase Common Stock), to non-affiliated third parties, related to these sales of common stock and common stock units.
	Issuance of Common Stock to Executive Officers
	On March 25, 2015, the Company issued an aggregate of 5,683,000 shares of common stock as stock-based compensation to its executive officers as follows: David R. LaVance, President and Chief Executive Officer – 3,613,250 shares; and Thomas S. Gifford, Executive Vice President and Chief Financial Officer – 2,069,750 shares. The total stock-based compensation expense associated with the issuance of these shares of common stock was $374,510.
	Stock Options
	The Company currently has two stock option/stock compensation plans in place: the 2010 Stock Incentive Plan and the 2012 Equity Incentive Plan (collectively, the “Equity Incentive Plans”).
	The 2010 Stock Incentive Plan was approved by the stockholders in September 2010. The Company had reserved for issuance an aggregate of 10,000,000 shares of common stock under the 2010 Stock Incentive Plan. As of March 31, 2015, stock options to purchase 3,846,920 shares of the Company’s common stock were outstanding under the 2010 Stock Incentive Plan and 90,500 shares of the Company’s common stock had been issued under the 2010 Stock Incentive Plan. As a result of the adoption of the Company’s 2012 Equity Incentive Plan, no further awards are permitted under the 2010 Stock Incentive Plan.
	The 2012 Equity Incentive Plan was approved by the stockholders in May 2012. The 2012 Equity Incentive Plan is designed to encourage and enable employees and directors of the Company to acquire or increase their holdings of common stock and other proprietary interests in the Company. The 2012 Equity Incentive Plan is intended to promote these individuals’ interests in the Company, thereby enhancing the efficiency, soundness, profitability, growth and stockholder value of the Company. The 2012 Equity Incentive Plan provides for grants and/or awards in the form of incentive and non-qualified stock option grants, stock appreciation rights, restricted stock awards, performance share awards, phantom stock awards and dividend equivalent awards.
	The original aggregate number of shares of common stock which could be awarded under the 2012 Equity Incentive Plan was 14,000,000 shares, subject to adjustment as provided in the 2012 Equity Incentive Plan. Effective February 25, 2015, as permitted under the 2012 Equity Incentive Plan, the Company’s board of directors increased the number of shares of common stock that could be awarded under the 2012 Equity Incentive Plan to 37,950,000 shares. As of March 31, 2015, options to purchase 450,000 shares of the Company’s common stock were outstanding under the 2012 Equity Incentive Plan and up to 37,500,000 shares of the Company’s common stock remain available for awards under the 2012 Equity Incentive Plan.
	Common stock grants and stock option awards under the Equity Incentive Plans were granted or issued at prices as determined by the Company’s compensation committee, but such prices were not less than the fair market value of the Company’s common stock on the date of grant or issuance. Stock options granted and outstanding to date consist of both incentive stock options and non-qualified stock options.
	A summary of stock option transactions under the Equity Incentive Plans during the three months ended March 31, 2015 is set forth below:
			Stock				Weighted					Aggregate
			Option				Average					Intrinsic
			Shares				Exercise					Value
							Price Per
							Common
							Share
	Outstanding at December 31, 2014			4,846,920			$	0.15			$	-
	Granted during the period			450,000			$	0.08				-
	Exercised during the period			-				-				-
	Terminated during the period			(1,000,000	)			-				-
	Outstanding at March 31, 2015			4,296,920			$	0.16			$	-
	Exercisable at March 31, 2015			3,934,420			$	0.16			$	-
	Exercisable at December 31, 2014			3,846,920			$	0.16			$	-
	The fair value of stock options granted during the three months ended March 31, 2015 was $21,613 and was calculated using the Black-Scholes pricing model with the following weighted average assumptions:
	Exercise price		$	0.08
	Grant date stock price		$	0.076
	Expected volatility			137	%
	Risk-free interest rates			2.08	%
	Risk of forfeiture			35	%
	Expected life (in years)			10
	Dividend yield			0	%
	The risk-free interest rate is based on a treasury instrument, the term of which is consistent with the expected life of the stock options at the date of grant. In projecting expected stock price volatility, the Company used historical stock price volatility of its common stock which the Company believes is representative of future volatility. The Company estimated the expected life of stock options based on historical experience using employee exercise and option expiration data.
	Information with respect to stock options outstanding and stock options exercisable as of March 31, 2015 is as follows:
					Stock Options Outstanding										Stock Options Exercisable
	Exercise				Number of Shares Available Under Outstanding Stock				Weighted Average Exercise Price Per Common Share				Weighted Average Remaining Contractual Life (Years)		Number of Shares Available for Purchase Under Outstanding Stock		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)
	Price				Options										Options
	$	0.08				450,000			$	0.08				9.9		87,500	$	0.08		9.9
	$	0.1				2,180,253			$	0.1				3.9		2,180,253	$	0.1		3.9
	$	0.2				833,333			$	0.2				7		833,333	$	0.2		7
	$	0.3				833,334			$	0.3				7		833,334	$	0.3		7
						4,296,920			$	0.16				5.7		3,934,420	$	0.16		5.4
	A summary of the non-vested shares subject to stock options granted under the Equity Incentive Plans as of March 31, 2015 is as follows:
			Stock				Weighted
			Option				Average
			Shares				Grant Date
							Fair Value
							Per Share
	Non-vested at December 31, 2014			1,000,000			$	0.09
	Granted during the period			450,000			$	0.08
	Vested during the period			(87,500	)		$	0.08
	Terminated during the period			(1,000,000	)		$	0.09
	Non-vested at March 31, 2015			362,500			$	0.08
	As of March 31, 2015, there was $21,035 of total unrecognized compensation cost related to non-vested, stock-based compensation arrangements granted under the Equity Incentive Plans. That cost is expected to be recognized over a weighted average period of thirty-eight months.
	Warrants to Purchase Common Stock
	A summary of warrant transactions during the three months ended March 31, 2015 is as follows:
			Warrant				Weighted				Aggregate Intrinsic
			Shares				Average				Value
							Exercise
							Price Per
			Common
			Share
Outstanding at December 31, 2014			28,908,878			$	0.12			$	42,006
Issued during the period			5,238,183			$	0.065				-
Exercised during the period			-				-				-
Terminated during the period			(10,675,000	)		$	0.12				-
Outstanding at March 31, 2015			23,472,061			$	0.1			$	79,974
Exercisable at March 31, 2015			23,472,061			$	0.1			$	79,974
Exercisable at December 31, 2014			28,908,878			$	0.12			$	42,006
Warrants issued by the Company contain exercise prices that were approved by the Company’s board of directors. Such exercise prices are generally not less than the quoted market price of the Company’s common stock on the date of issuance. Warrants currently issued either vested immediately or over a period of up to three years and have a maximum term of ten years from the date of issuance.
The fair value of the warrants issued during the three months ended March 31, 2015 was $168,813 and was calculated using the Black-Scholes pricing model with the following weighted average assumptions:
Exercise price			$0.06 - $0.066
Grant date stock price		$	0.067
Expected volatility			128	%
Risk-free interest rates			0.87	%
Risk of forfeiture			35	%
Expected life (in years)			3
Dividend yield			0	%
Information with respect to warrants outstanding and warrants exercisable at March 31, 2015 is as follows:
				Warrants Outstanding										Warrants Exercisable
Range of				Number of Shares Available Under Outstanding Warrants				Weighted Average Remaining Contractual Life (Years)				Weighted Average Exercise Price Per Common Share		Number of Shares Available for Purchase Under Outstanding Warrants		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price Per Common Share
Exercise Prices
$	0.03 - 0.04				1,151,567				1.8			$	0.04		1,151,567		1.8	$	0.04
$	0.06 - 0.07				10,344,244				4.2			$	0.07		10,344,244		4.2	$	0.07
$	0.08 - 0.09				6,320,000				6.1			$	0.09		6,320,000		6.1	$	0.09
$	0.2				5,656,250				0.5			$	0.2		5,656,250		0.5	$	0.2
					23,472,061				3.7			$	0.1		23,472,061		3.7	$	0.1
As of March 31, 2015, there were no non-vested shares subject to warrants and no unrecognized compensation cost related to warrants.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	8. Stock-Based Compensation
	During the three months ended March 31, 2015 and 2014, the Company recorded stock-based compensation expense as follows:
		Three
		Months Ended
		March 31,
		2015		2014
	General and administrative	$	187,357	$	26,837
	Sales and marketing		131,554		2,520
	Research and development		56,177		1,080
	Total	$	375,088	$	30,437
	For the three months ended March 31, 2015 and 2014, the Company recorded stock-based compensation expense related to common stock and stock options granted to employees and directors of $375,088 and $10,437, respectively. For the three months ended March 31, 2015 and 2014, the Company recorded stock-based compensation expense related to common stock and warrants granted to non-employees of $0 and $20,000, respectively.

Net_Loss_Per_Common_Share

Net Loss Per Common Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Net Loss Per Common Share	9. Net Loss Per Common Share
	Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflect, in periods in which they have a dilutive effect, the impact of common shares issuable upon exercise of stock options and warrants and conversion of convertible debt that are not deemed to be anti-dilutive. The dilutive effect of the outstanding stock options and warrants is computed using the treasury stock method.
	For the three months ended March 31, 2015, diluted net loss per share did not include the effect of 4,296,920 shares of common stock issuable upon the exercise of outstanding stock options, 23,472,061 shares of common stock issuable upon the exercise of outstanding warrants and 4,823,750 shares of common stock issuable upon the conversion of convertible debt, as their effect would be anti-dilutive.
	For the three months ended March 31, 2014, diluted net loss per share did not include the effect of 4,980,254 shares of common stock issuable upon the exercise of outstanding stock options, 36,844,565 shares of common stock issuable upon the exercise of outstanding warrants and 4,823,750 shares of common stock issuable upon the conversion of convertible debt, as their effect would be anti-dilutive.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies
	Litigation with Former Executive Vice President – Operations
	On June 17, 2014, a civil complaint was filed against the Company and one of its directors, E. Wayne Kinsey, III, in the Court of Common Pleas, County of Horry, State of South Carolina, by Marion Sofield, the Company’s former Executive Vice President - Operations. In her complaint, Ms. Sofield alleges breach of contract and fraud/fraudulent inducement by the Company against her with regard to her employment agreement and the termination of her employment. Ms. Sofield also alleges the Company and Mr. Kinsey engaged in a civil conspiracy and unfair trade practices and that Mr. Kinsey engaged in tortious interference. Ms. Sofield claims that she is owed additional compensation under her terminated employment agreement, and is seeking the recovery of such compensation as well as attorney’s fees and punitive damages.
	On July 18, 2014, the Company filed a motion to dismiss this state court action due to the binding arbitration clause contained in Ms. Sofield’s employment agreement that applies to a majority of the allegations in the complaint. On December 8, 2014, the court entered a consent order that: (a) granted the Company’s request to compel binding arbitration of the breach of contract and fraud claims; and (b) stayed the remaining causes of action in the South Carolina state court until the aforementioned binding arbitration process is complete. The Company does not believe there is any merit to Ms. Sofield’s allegations and will continue to vigorously defend this action.

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Components of Property and Equipment, on Net Basis	As of March 31, 2015 and December 31, 2014, property and equipment, on a net basis, consisted of the following:
		31-Mar-15			31-Dec-14
	Leasehold improvements	$	328,977		$	328,977
	Equipment		476,807			437,504
			805,784			766,481
	Less: Accumulated depreciation		(529,621	)		(507,013	)
		$	276,163		$	259,468

Accrued_Expenses_Tables

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Components of Accrued Expenses	As of March 31, 2015 and December 31, 2014, accrued expenses consisted of the following:
		31-Mar-15		31-Dec-14
	Accrued compensation	$	232,979	$	253,305
	Accrued penalty		-		87,344
	Accrued interest (see Note 5)		37,453		27,321
	Accrued professional fees		2,750		22,000
	Accrued consulting fees and other expenses		30,128		13,550
		$	303,310	$	403,520

Stockholders_Equity_Deficiency1

Stockholders' Equity (Deficiency) (Tables)	3 Months Ended
	Mar. 31, 2015
Summary of Stock Option Transactions	A summary of stock option transactions under the Equity Incentive Plans during the three months ended March 31, 2015 is set forth below:
			Stock				Weighted					Aggregate
			Option				Average					Intrinsic
			Shares				Exercise					Value
							Price Per
							Common
							Share
	Outstanding at December 31, 2014			4,846,920			$	0.15			$	-
	Granted during the period			450,000			$	0.08				-
	Exercised during the period			-				-				-
	Terminated during the period			(1,000,000	)			-				-
	Outstanding at March 31, 2015			4,296,920			$	0.16			$	-
	Exercisable at March 31, 2015			3,934,420			$	0.16			$	-
	Exercisable at December 31, 2014			3,846,920			$	0.16			$	-
Summary of Fair Value Assumption of Stock Options Granted Using Black-Scholes Pricing Model	The fair value of stock options granted during the three months ended March 31, 2015 was $21,613 and was calculated using the Black-Scholes pricing model with the following weighted average assumptions:
	Exercise price		$	0.08
	Grant date stock price		$	0.076
	Expected volatility			137	%
	Risk-free interest rates			2.08	%
	Risk of forfeiture			35	%
	Expected life (in years)			10
	Dividend yield			0	%
Summary of Stock Options Outstanding and Exercisable	Information with respect to stock options outstanding and stock options exercisable as of March 31, 2015 is as follows:
					Stock Options Outstanding										Stock Options Exercisable
	Exercise				Number of Shares Available Under Outstanding Stock				Weighted Average Exercise Price Per Common Share				Weighted Average Remaining Contractual Life (Years)		Number of Shares Available for Purchase Under Outstanding Stock		Weighted Average Exercise Price Per Common Share		Weighted Average Remaining Contractual Life (Years)
	Price				Options										Options
	$	0.08				450,000			$	0.08				9.9		87,500	$	0.08		9.9
	$	0.1				2,180,253			$	0.1				3.9		2,180,253	$	0.1		3.9
	$	0.2				833,333			$	0.2				7		833,333	$	0.2		7
	$	0.3				833,334			$	0.3				7		833,334	$	0.3		7
						4,296,920			$	0.16				5.7		3,934,420	$	0.16		5.4
Summary of Non Vested Stock Options Granted	A summary of the non-vested shares subject to stock options granted under the Equity Incentive Plans as of March 31, 2015 is as follows:
			Stock				Weighted
			Option				Average
			Shares				Grant Date
							Fair Value
							Per Share
	Non-vested at December 31, 2014			1,000,000			$	0.09
	Granted during the period			450,000			$	0.08
	Vested during the period			(87,500	)		$	0.08
	Terminated during the period			(1,000,000	)		$	0.09
	Non-vested at March 31, 2015			362,500			$	0.08
Summary of Warrant Transactions	A summary of warrant transactions during the three months ended March 31, 2015 is as follows:
			Warrant				Weighted				Aggregate Intrinsic
			Shares				Average				Value
							Exercise
							Price Per
							Common
							Share
	Outstanding at December 31, 2014			28,908,878			$	0.12			$	42,006
	Issued during the period			5,238,183			$	0.065				-
	Exercised during the period			-				-				-
	Terminated during the period			(10,675,000	)		$	0.12				-
	Outstanding at March 31, 2015			23,472,061			$	0.1			$	79,974
	Exercisable at March 31, 2015			23,472,061			$	0.1			$	79,974
	Exercisable at December 31, 2014			28,908,878			$	0.12			$	42,006
Summary of Warrants Outstanding and Exercisable	Information with respect to warrants outstanding and warrants exercisable at March 31, 2015 is as follows:
					Warrants Outstanding										Warrants Exercisable
	Range of				Number of Shares Available Under Outstanding Warrants				Weighted Average Remaining Contractual Life (Years)				Weighted Average Exercise Price Per Common Share		Number of Shares Available for Purchase Under Outstanding Warrants		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price Per Common Share
	Exercise Prices
	$	0.03 - 0.04				1,151,567				1.8			$	0.04		1,151,567		1.8	$	0.04
	$	0.06 - 0.07				10,344,244				4.2			$	0.07		10,344,244		4.2	$	0.07
	$	0.08 - 0.09				6,320,000				6.1			$	0.09		6,320,000		6.1	$	0.09
	$	0.2				5,656,250				0.5			$	0.2		5,656,250		0.5	$	0.2
						23,472,061				3.7			$	0.1		23,472,061		3.7	$	0.1
Warrant [Member]
Summary of Fair Value Assumption of Stock Options Granted Using Black-Scholes Pricing Model	The fair value of the warrants issued during the three months ended March 31, 2015 was $168,813 and was calculated using the Black-Scholes pricing model with the following weighted average assumptions:
	Exercise price			$0.06 - $0.066
	Grant date stock price		$	0.067
	Expected volatility			128	%
	Risk-free interest rates			0.87	%
	Risk of forfeiture			35	%
	Expected life (in years)			3
	Dividend yield			0	%

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock-Based Compensation	During the three months ended March 31, 2015 and 2014, the Company recorded stock-based compensation expense as follows:
		Three
		Months Ended
		March 31,
		2015		2014
	General and administrative	$	187,357	$	26,837
	Sales and marketing		131,554		2,520
	Research and development		56,177		1,080
	Total	$	375,088	$	30,437

Basis_of_Presentation_Details_

Basis of Presentation (Details Narrative) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working capital	$752,400
Accumulated deficit	$22,776,465	$21,714,820

Inventory_Details_Narrative

Inventory (Details Narrative) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventory	$95,706	$117,690

Property_and_Equipment_Compone

Property and Equipment - Components of Property and Equipment, on Net Basis (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Leasehold improvements	$328,977	$328,977
Equipment	476,807	437,504
Property and equipment, Gross	805,784	766,481
Less: Accumulated depreciation	-529,621	-507,013
Property and equipment, net	$276,163	$259,468

Accrued_Expenses_Components_of

Accrued Expenses - Components of Accrued Expenses (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued compensation	$232,979	$253,305
Accrued penalty		87,344
Accrued interest (see Note 5)	37,453	27,321
Accrued professional fees	2,750	22,000
Accrued consulting fees and other expenses	30,128	13,550
Accrued liabilities, total	$303,310	$403,520

Convertible_Debentures_Details

Convertible Debentures (Details Narrative) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Aug. 21, 2012	Apr. 26, 2007	Dec. 31, 2014	Jul. 07, 2011	Sep. 23, 2011
Debt Instrument [Line Items]
Interest expense related to convertible debenture	$740	$740
Convertible debenture outstanding principal	25,000				25,000
Accrued and unpaid interest on convertible debt	14,181				13,441
Zanett August 2012 Debenture [Member]
Debt Instrument [Line Items]
Convertible debenture, maturity date	21-Aug-15
Convertible debenture, interest rate	8.00%
Convertible debenture, conversion price	$0.10		$0.10
Common stock issued as payment on principal and interest on convertible debentures, shares			4,761,250
Interest expense related to convertible debenture	9,392	9,392
Convertible debenture outstanding principal	476,125				476,125
Accrued and unpaid interest on convertible debt	23,272				13,880
Debenture term	3 years
Common stock price per share	$0.10		$0.05
Zanett August 2012 Debenture [Member] | Maximum [Member]
Debt Instrument [Line Items]
Common stock price per share	$0.15
Private Placement [Member]
Debt Instrument [Line Items]
Convertible debenture issued, principal amount				25,000
Convertible debenture, maturity date				2-Jan-09
Convertible debenture, interest rate				12.00%
Convertible debenture, conversion price				$0.40
Common stock issued as payment on principal and interest on convertible debentures, shares				62,500
Zanett Opportunity Fund, Ltd [Member] | 8% Convertible Debenture [Member] | Zanett August 2012 Debenture [Member]
Debt Instrument [Line Items]
Convertible debenture issued, principal amount			476,125
Zanett Opportunity Fund, Ltd [Member] | 8% Convertible Debenture [Member] | Zanett July 2011 Debenture [Member]
Debt Instrument [Line Items]
Convertible debenture issued, principal amount						376,125
Zanett Opportunity Fund, Ltd [Member] | 8% Convertible Secured Promissory Note [Member] | Zanett September 2011 Note [Member]
Debt Instrument [Line Items]
Convertible debenture issued, principal amount							$100,000

Note_Payable_Details_Narrative

Note Payable (Details Narrative) (USD $)	0 Months Ended	3 Months Ended
	Jun. 17, 2013	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
	Machine
Debt Instrument [Line Items]
Interest expense related to benchmark note		$740	$740
Asset Purchase Agreement [Member]
Debt Instrument [Line Items]
Number of machines purchase	19
Purchase price of asset	190,000
Payment in closing of asset purchase agreement	38,000
Issuance of promissory note principal balance	152,000	26,829		46,546
Convertible promissory notes, interest percentage	7.00%
Description of payment term	Twenty-four monthly payments.
Periodic payment	6,805
Convertible promissory notes, commencing date	1-Aug-13
Interest expense related to benchmark note		$6,852	$2,029

Stockholders_Equity_Deficiency2

Stockholders' Equity (Deficiency) (Details Narrative) (USD $)	0 Months Ended		3 Months Ended	0 Months Ended
	Mar. 25, 2015	Feb. 09, 2015	Mar. 31, 2015	Feb. 09, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock shares sold		36,500,000
Number of common stock sold		$1,460,000
Common stock sales price per share		$0.04
Issuance of common stock shares		7,575,758
Issuance of warrants to purchase of common stock shares		3,787,880
Issuance of warrants to purchase of common stock		500,000
Warrant exercise price per share		$0.07
Warrant term		3 years
Warrant description		the warrants are callable by the Company in the event that the closing price of its common stock for at least fifteen trading days in any consecutive twenty-trading-day period is equal to or greater than $0.132, provided that at least six months have lapsed from the issuance date of the warrants
Offering cost paid		46,050
Issuance of common stock shares for payment of offering cost		1,055,303
Issuance of common stock for payment of offering cost		56,000
Stock based compensation	374,510
Fair value of stock options granted			21,613
Fair value adjustment of warrants			168,813
Warrant [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant vested period			3 years
Warrant [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant vested period			10 years
2010 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock reserved			10,000,000
Issuance of stock option to purchases of common stock shares			3,846,920
Common stock stock shares issued under plan			90,500
2012 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock shares as stock-based compensation			37,500,000
Common stock stock shares issued under plan			450,000
Number of common stock shares award under plan			14,000,000
Unrecognized compensation cost related to non-vested			$21,035
Recognized non vested over a weighted average period			38 months
Executive Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock shares as stock-based compensation	5,683,000
David R. LaVance [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock shares as stock-based compensation	3,613,250
Thomas S. Gifford [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock shares as stock-based compensation	2,069,750
Board of Directors [Member] | 2012 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock shares increased under plan			37,950,000
Non-Affiliated Third Parties [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of warrants to purchase of common stock shares				1,450,303

Stockholders_Equity_Deficiency3

Stockholders' Equity (Deficiency) - Summary of Stock Option Transactions (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Stockholders Equity Deficiency - Summary Of Stock Option Transactions Details
Stock Option Outstanding, Number, Beginning Balance	4,846,920
Stock Option Granted during the period, Shares	450,000
Stock Option Exercised during the period, Shares
Stock Option Terminated during the period, Shares	-1,000,000
Stock Option Outstanding shares, Ending balance	4,296,920
Stock Option Exercisable, Beginning balance	3,846,920
Stock Option Exercisable, Ending balance	3,934,420
Stock Option Outstanding, Weighted Average Exercise Price, Beginning Balance	$0.15
Stock Option Grants in Period, Weighted Average Exercise Price	$0.08
Stock Option Exercises in Period, Weighted Average Exercise Price
Stock OptionTerminated, Weighted Average Exercise Price
Stock Option Outstanding, Weighted Average Exercise Price, Ending balance	$0.16
Stock Option Exercisable, Weighted Average Exercise Price, Beginning balance	$0.16
Stock Option Exercisable, Weighted Average Exercise Price, Ending balance	$0.16
Stock Option Outstanding, Aggregate Intrinsic Value, Beginning balance
Stock Option Granted Aggregate Intrinsic Value
Stock Option Exercised Aggregate Intrinsic Value
Stock Option Outstanding, Aggregate Intrinsic Value, Ending balance
Stock Option Exercisable, Intrinsic Value Beginning balance
Stock Option Exercisable, Intrinsic Value Ending balance

Stockholders_Equity_Deficiency4

Stockholders' Equity (Deficiency) - Summary of Fair Value Assumption of Stock Options Granted Using Black-Scholes Pricing Model (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$0.08
Grant date stock price	$0.08
Expected volatility	137.00%
Risk-free interest rates	2.08%
Risk of forfeiture	35.00%
Expected life (in years)	10 years
Dividend yield	0.00%
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date stock price	$0.07
Expected volatility	128.00%
Risk-free interest rates	0.87%
Risk of forfeiture	35.00%
Expected life (in years)	3 years
Dividend yield	0.00%
Warrant [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$0.06
Warrant [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price	$0.07

Stockholders_Equity_Deficiency5

Stockholders' Equity (Deficiency) - Summary of Stock Options Outstanding and Exercisable (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares Available Under Outstanding Stock Options	4,296,920	4,846,920
Weighted Average Exercise Price Per Common Share	$0.16	$0.15
Weighted Average Remaining Contractual Life (Years)	5 years 8 months 12 days
Number of Shares Available for Purchase Under Outstanding Stock Options	3,934,420	3,846,920
Weighted Average Exercise Price Per Common Share	$0.16	$0.16
Weighted Average Remaining Contractual Life (Years)	5 years 4 months 24 days
Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices	$0.08
Number of Shares Available Under Outstanding Stock Options	450,000
Weighted Average Exercise Price Per Common Share	$0.08
Weighted Average Remaining Contractual Life (Years)	9 years 10 months 24 days
Number of Shares Available for Purchase Under Outstanding Stock Options	87,500
Weighted Average Exercise Price Per Common Share	$0.08
Weighted Average Remaining Contractual Life (Years)	9 years 10 months 24 days
Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices	$0.10
Number of Shares Available Under Outstanding Stock Options	2,180,253
Weighted Average Exercise Price Per Common Share	$0.10
Weighted Average Remaining Contractual Life (Years)	3 years 10 months 24 days
Number of Shares Available for Purchase Under Outstanding Stock Options	2,180,253
Weighted Average Exercise Price Per Common Share	$0.10
Weighted Average Remaining Contractual Life (Years)	3 years 10 months 24 days
Range Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices	$0.20
Number of Shares Available Under Outstanding Stock Options	833,333
Weighted Average Exercise Price Per Common Share	$0.20
Weighted Average Remaining Contractual Life (Years)	7 years
Number of Shares Available for Purchase Under Outstanding Stock Options	833,333
Weighted Average Exercise Price Per Common Share	$0.20
Weighted Average Remaining Contractual Life (Years)	7 years
Range Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of exercise prices	$0.30
Number of Shares Available Under Outstanding Stock Options	833,334
Weighted Average Exercise Price Per Common Share	$0.30
Weighted Average Remaining Contractual Life (Years)	7 years
Number of Shares Available for Purchase Under Outstanding Stock Options	833,333
Weighted Average Exercise Price Per Common Share	$0.30
Weighted Average Remaining Contractual Life (Years)	7 years

Stockholders_Equity_Deficiency6

Stockholders' Equity (Deficiency) - Summary of Non Vested Stock Options Granted (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Stock Option Nonvested, Number, Beginning Balance	1,000,000
Stock Option Granted during the period	450,000
Stock Option Vested during the period	-87,500
Stock Option Terminated during the period	-1,000,000
Stock Option Non-vested Balance	362,500
Stock Option Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance	$0.09
Stock Option Weighted Average Grant Date Fair Value Per Share, Granted	$0.08
Stock Option Weighted Average Grant Date Fair Value Per Share, Vested	$0.08
Stock Option Weighted Average Grant Date Fair Value Per Share, Terminated	$0.09
Stock Option Weighted Average Grant Date Fair Value Per Share, Ending Balance	$0.08

Stockholders_Equity_Deficiency7

Stockholders' Equity (Deficiency) - Summary of Warrant Transactions (Details) (Warrant [Member], USD $)	3 Months Ended
	Mar. 31, 2015
Warrant [Member]
Warrant Shares Outstanding	28,908,878
Warrant Shares Issued during the period	5,238,183
Warrant Shares Exercised during the period
Warrant Shares Terminated during the period	-10,675,000
Warrant Shares Outstanding	23,472,061
Warrant Shares Exercisable Beginning Balance	28,908,878
Warrant Shares Exercisable Ending Balance	23,472,061
Weighted Average Exercise Price Per Common Share Outstanding	$0.12
Weighted Average Exercise Price Per Common Share Issued during the period	$0.07
Weighted Average Exercise Price Per Common Share Exercised during the period
Weighted Average Exercise Price Per Common Share Terminated during the period	$0.12
Weighted Average Exercise Price Per Common Share Outstanding	$0.10
Weighted Average Exercise Price Per Common Share Exercisable Beginning Balance	$0.12
Weighted Average Exercise Price Per Common Share Exercisable Ending Balance	$0.10
Aggregate Intrinsic Value Outstanding Beginning Balance	$42,006
Aggregate Intrinsic Value Issued during the period
Aggregate Intrinsic Value Exercised during the period
Aggregate Intrinsic Value Terminated during the period
Aggregate Intrinsic Value Outstanding Ending Balance	$79,974
Aggregate Intrinsic Value Exercisable Beginning Balance	$42,006
Aggregate Intrinsic Value Exercisable Ending Balance	$79,974

Stockholders_Equity_Deficiency8

Stockholders' Equity (Deficiency) - Summary of Warrants Outstanding and Exercisable (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Number of Shares Available Under Outstanding Stock Options/ Warrants	4,296,920	4,846,920
Weighted Average Remaining Contractual Life (Years)	5 years 8 months 12 days
Weighted Average Exercise Price Per Common Share	$0.16	$0.15
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants	3,934,420	3,846,920
Weighted Average Remaining Contractual Life (Years)	5 years 4 months 24 days
Weighted Average Exercise Price Per Common Share	$0.16	$0.16
Range One [Member]
Number of Shares Available Under Outstanding Stock Options/ Warrants	450,000
Weighted Average Remaining Contractual Life (Years)	9 years 10 months 24 days
Weighted Average Exercise Price Per Common Share	$0.08
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants	87,500
Weighted Average Remaining Contractual Life (Years)	9 years 10 months 24 days
Weighted Average Exercise Price Per Common Share	$0.08
Range Two [Member]
Number of Shares Available Under Outstanding Stock Options/ Warrants	2,180,253
Weighted Average Remaining Contractual Life (Years)	3 years 10 months 24 days
Weighted Average Exercise Price Per Common Share	$0.10
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants	2,180,253
Weighted Average Remaining Contractual Life (Years)	3 years 10 months 24 days
Weighted Average Exercise Price Per Common Share	$0.10
Range Three [Member]
Number of Shares Available Under Outstanding Stock Options/ Warrants	833,333
Weighted Average Remaining Contractual Life (Years)	7 years
Weighted Average Exercise Price Per Common Share	$0.20
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants	833,333
Weighted Average Remaining Contractual Life (Years)	7 years
Weighted Average Exercise Price Per Common Share	$0.20
Range Four [Member]
Number of Shares Available Under Outstanding Stock Options/ Warrants	833,334
Weighted Average Remaining Contractual Life (Years)	7 years
Weighted Average Exercise Price Per Common Share	$0.30
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants	833,333
Weighted Average Remaining Contractual Life (Years)	7 years
Weighted Average Exercise Price Per Common Share	$0.30
Warrant [Member]
Number of Shares Available Under Outstanding Stock Options/ Warrants	23,472,061
Weighted Average Remaining Contractual Life (Years)	3 years 8 months 12 days
Weighted Average Exercise Price Per Common Share	$0.10
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants	23,472,061
Weighted Average Remaining Contractual Life (Years)	3 years 8 months 12 days
Weighted Average Exercise Price Per Common Share	$0.10
Warrant [Member] | Range One [Member]
Range of Exercise Prices, Lower Limit	$0.03
Range of Exercise Prices, Upper Limit	$0.04
Number of Shares Available Under Outstanding Stock Options/ Warrants	1,151,567
Weighted Average Remaining Contractual Life (Years)	1 year 9 months 18 days
Weighted Average Exercise Price Per Common Share	$0.04
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants	1,151,567
Weighted Average Remaining Contractual Life (Years)	1 year 9 months 18 days
Weighted Average Exercise Price Per Common Share	$0.04
Warrant [Member] | Range Two [Member]
Range of Exercise Prices, Lower Limit	$0.06
Range of Exercise Prices, Upper Limit	$0.07
Number of Shares Available Under Outstanding Stock Options/ Warrants	10,344,244
Weighted Average Remaining Contractual Life (Years)	4 years 2 months 12 days
Weighted Average Exercise Price Per Common Share	$0.07
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants	10,344,244
Weighted Average Remaining Contractual Life (Years)	4 years 2 months 12 days
Weighted Average Exercise Price Per Common Share	$0.07
Warrant [Member] | Range Three [Member]
Range of Exercise Prices, Lower Limit	$0.08
Range of Exercise Prices, Upper Limit	$0.09
Number of Shares Available Under Outstanding Stock Options/ Warrants	6,320,000
Weighted Average Remaining Contractual Life (Years)	6 years 1 month 6 days
Weighted Average Exercise Price Per Common Share	$0.09
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants	6,320,000
Weighted Average Remaining Contractual Life (Years)	6 years 1 month 6 days
Weighted Average Exercise Price Per Common Share	$0.09
Warrant [Member] | Range Four [Member]
Range of exercise prices	$0.20
Number of Shares Available Under Outstanding Stock Options/ Warrants	5,656,250
Weighted Average Remaining Contractual Life (Years)	6 months
Weighted Average Exercise Price Per Common Share	$0.20
Number of Shares Available for Purchase Under Outstanding Stock Options/Warrants	5,656,250
Weighted Average Remaining Contractual Life (Years)	6 months
Weighted Average Exercise Price Per Common Share	$0.20

StockBased_Compensation_Detail

Stock-Based Compensation (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Stock-based compensation expense related to stock options and warrants	$375,088	$30,437
Employees and Director [Member]
Stock-based compensation expense related to stock options and warrants	375,088	10,437
Nonemployees [Member]
Stock-based compensation expense related to stock options and warrants	$0	$20,000

StockBased_Compensation_Schedu

Stock-Based Compensation - Schedule of Stock-Based Compensation (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$375,088	$30,437
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	187,357	26,837
Sales and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	131,554	2,520
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$56,177	$1,080

Net_Loss_Per_Common_Share_Deta

Net Loss Per Common Share (Details Narrative)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Outstanding Stock Options [Member]
Anti-dilutive	4,296,920	4,980,254
Outstanding Warrants [Member]
Anti-dilutive	23,472,061	36,844,565
Conversion of Convertible Debt [Member]
Anti-dilutive	4,823,750	4,823,750